Emanuela Zappulo

New β-Lactam–β-Lactamase Inhibitor Combinations

Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review

Hepatitis C virus drug resistance–associated substitutions: State of the art summary

Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Critical comments on the WHO-UNEP State of the Science of Endocrine Disrupting Chemicals – 2012

Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance

A review on recent developments of indole-containing antiviral agents

A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase

Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view

Taming a beast: lessons from the domestication of hepatitis C virus

EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals

NS5B polymerase inhibitors in phase II clinical trials for HCV infection

Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus

Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment

Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus

Etiopathogenesis of autism spectrum disorders: Fitting the pieces of the puzzle together

The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C

Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus

GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era

Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?

Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience

Beclabuvir for the treatment of hepatitis C

Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development

Discontinued drugs in 2012 – 2013: hepatitis C virus infection